ABSTRACT Antibiotics have played a critical role in the prevention, control, and treatment of bacterial diseases in humans and animals, and as growth promoters (AGPs) when used at sub-therapeutic concentrations in animal production. Numerous hypotheses have been proposed for the effectiveness of AGPs, which have largely centered on the beneficial modulation of the intestinal microbiota. However, these hypotheses have been doubted by some researchers, as AGPs are fed at concentrations that would typically be below minimum inhibitory concentrations (sub-MIC) for the antibiotic used. More recently, pro-inflammatory immune responses have been associated with poor growth performance, and this, along with reported direct, antiinflammatory effects of some antibiotics, have led to suggestions that reducing the nutrient cost of (intestinal) inflammation may explain the growth promoting or permitting effect of AGPs. However, doubts about antibacterial effects of AGPs, and the search for alternative explanations, overlook the sub-MIC effects of antibiotics. This paper summarizes some of the reported sub-MIC effects of antibiotics and considers these in the context of helping to explain the mode of action of AGPs and effects seen in studies in vivo. This leads to suggestions for the features that alternatives to AGPs could exhibit to achieve similar performance efficacy as AGPs.
INTRODUCTION
The term "antibiotic" translates as "against life." More specifically, antibiotics are able to inhibit or kill bacteria. Since their fortuitous discovery, antibiotics have played a critical role in the prevention, control and treatment of bacterial diseases in both humans and animals. In animal production, antibiotics have also been used at sub-therapeutic concentrations as growth promoters (AGPs) and have thus made a significant contribution to animal health, welfare and performance, and the general productivity of the industry. However, soon after the discovery that AGPs could enhance growth and feed efficiency, concerns were expressed about a potential relationship between such use of antibiotics and the development of resistance by bacteria (Swann, 1969) . These concerns ultimately lead to prohibitive legislation/guidance by individual countries and regions (Castanon, 2007) nary Feed Directive, 2015) . Such has been the perceived benefit of AGPs to animal production that 1) the industry has sought to identify alternative additives or strategies to fill the void, and 2) there still remains a desire (and perhaps a need) to better understand the mode of action of AGPs.
Numerous hypotheses have been proposed to explain how AGPs enable animals to grow faster and more efficiently. Most of these, obviously, focus on or are related to the antibacterial effects of antibiotics. Typically proposed mechanisms include 1) reducing total microbial density in the gastrointestinal tract (GIT), 2) promoting a more favorable GIT microbial balance and/or reducing sub-clinical infections, 3) reducing the production of potentially toxic bacterial metabolites, and 4) better absorption of nutrients through a thinner intestinal epithelium (Gaskins et al., 2002) . More recently, it has been proposed that AGPs may work by directly inhibiting the negative effects of intestinal inflammatory cells (Niewold, 2007) . Although the intestinal microbiota provides numerous benefits to the host (e.g., aids immune development, provides colonization resistance to pathogens, produces short-chain fatty acids and some vitamins, etc.), the microbiota is also a significant nutrient cost (e.g., competes for available nutrients, necessitates maintenance of intestinal and immune tissue, 3104 etc.) (Dibner and Richards, 2005) . In younger animals, meta-analysis has revealed that AGPs improve growth rates by up to 16% and feed efficiency by up to 7% (Cromwell, 2002) .
CENTRAL ROLE OF THE GUT MICROBIOTA IN THE AGP RESPONSE
Germ-free animals typically show no response to AGPs (e.g., Coates et al., 1963) , and it is widely accepted that the degree of (microbial) challenge in experimental studies determines the probability, or magnitude, of a response to AGPs. These response criteria underline the central role of microbial exposure to the AGP response. Numerous studies have reported modification of the GIT microbiota by AGPs (Gaskins et al., 2002; Dumonceaux et al., 2006; Wise and Siragusa, 2007; Lu et al., 2008; La-ongkhum et al., 2011) . These studies have reported, although at times conflicting, that AGPs reduce certain bacterial species (e.g., species of Lactobacillus and Streptococcus) and overall community diversity, increase abundance of lactobacilli in proximal GIT locations with a differing effect (no change or decreased) in distal regions, predominantly alter the ileal microbiota (lactobacilli dominant and Enterobacteriaceae reduced) and promote (seemingly non-pathogenic) Clostridia. It is striking that the most commonly used AGPs are predominantly active against gram-positive bacteria (Table 1) , and so effects on bacteria within this grouping are not unexpected. Interpretation, particularly of earlier studies, is hampered by the fact that we now know that the GIT microbiota is a complex ecosystem and that much of the GIT bacterial community is not culturable or well characterized. However, gut microbiota modification is a relatively consistent feature of AGP studies, which must be a direct or indirect result of AGP supplementation.
THE SUB-INHIBITORY EFFECTS OF ANTIBIOTICS
More recently, doubts have been expressed about the likelihood of a direct antibiotic effect on the GIT microbial community by AGPs, which is central to (most of) their proposed mode(s) of action (Niewold, 2007) . These doubts are largely based on the low concentrations of antibiotics when fed as AGPs, which may be below reported minimum inhibitory concentrations (MIC) for the particular antibiotic. There are two key antibacterial terms that are typically determined to describe the effectiveness of an antimicrobial agent against strains of bacteria; 1) MIC and 2) minimum bactericidal concentration (MBC).
MIC is defined as the lowest concentration of an antimicrobial that prevents the visible growth of the target bacteria (bacteriostatic effect). MBC is defined as the lowest concentration of an antimicrobial that causes bacterial cell death (bactericidal effect).
Outside the area of antimicrobial research, the MIC is often considered to be the lowest concentration of an antimicrobial that has any effect on target bacteria. Indeed, the therapeutic efficacy of antibiotics in vivo is considered to relate to the inhibition of bacterial growth through antibiotic concentrations, typically measured in serum, exceeding the MIC (Shryock et al., 1998) . However, AGPs are not used for a therapeutic effect, and it is important to emphasize that the MIC is defined by the word visible growth. Therefore, MIC does not include/determine effects on bacterial growth characteristics or function at lower concentrations of the antibiotic. Early studies established that exposing Staphylococcus aureus to sub-inhibitory concentrations (sub-MICs) of nafcillin increased susceptibility to phagocytosis (Friedman and Warren, 1974) , while sub-MICs of ampicillin reduced Escherichia coli attachment to human uroepithelial cells in vitro (Sandberg et al., 1979) . Even at this stage, it was recognized that antibiotics at sub-MICs could modify bacterial properties to such an extent that the bacteria are rendered more susceptible to host defense mechanisms and that such antibiotic action would not be detected by traditional screening methodology (e.g., MIC) (Taylor et al., 1981) . Subsequently, Hacker et al. (1993) reported that sub-MICs of aztreonam, gentamicin, clindamycin, and trimethoprim strongly suppressed the expression of a virulence gene cluster of pathogenic E. coli, while Nanduri et al. (2006) demonstrated that subMICs of amoxicillin, chlortetracycline, and enrofloxacin inhibited growth kinetics and altered protein expression by Pasteurella multocida. Some of these protein expression changes were considered to enhance antibiotic activity, while others may represent a compensatory response by the bacterium to the antibiotic. Biofilm formation can also be considered a major virulence factor as it helps provide bacterial protection and can aid infection (Van Mellaert et al., 2012) , with quorum sensing (cell-to-cell communication) playing a key role in the formation of biofilms (Dong et al., 2012) . A number of studies have shown that antimicrobials at sub-MICs can inhibit biofilm formation (Cerca et al., 2005; Starner et al., 2008) . Although, by definition, antibiotics at sub-MICs do not affect the (visible) growth of bacteria (in vitro), they can influence their growth profile. Drummond et al. (2003) reported that the most common effect of sub-MICs of vancomycin, metronidazole, amoxycillin, clindamycin, cefoxitin, and ceftriaxone on 3 strains of Clostridium difficile was to increase the initial lag phase of growth (i.e., period of no bacterial cell multiplication) by approximately 4 h. In addition, antibiotics, including chlortetracycline, at sub-MICs have been demonstrated to markedly reduce the growth rates of Mannheimia haemolytica and Haemophilus somnus, which it was suggested would be advantageous to the host in helping facilitate clearance of infections (Reeks et al., 2005) . The antimicrobials were used in the above studies over a concentration range of 1 2 to 1 / 32 of the MIC for the specified bacteria. There is, therefore, clear evidence that antibiotics at sub-MICs can affect bacterial growth characteristics, protein and virulence factor expression/formation (e.g., cell adhesion capability, toxin production, biofilm formation, etc.) and susceptibility to host immune responses. Moreover, when used therapeutically, some antibiotics may frequently have serum concentrations below the relevant MIC, which suggests that the relationship between the antibiotic's MIC and in vivo efficacy is not straightforward (Butts, 1994) . In fact, sub-MIC antibiotic concentrations would seem to contribute to clinical efficacy by subverting bacterial pathogens for more rapid and effective neutralization and clearance by the host immune system (Shryock et al., 1998) , even though sub-MIC antibiotic use may select for bacterial resistance, which in itself implies sub-MIC bacterial selection pressure (Andersson and Hughes, 2014) . Thus, even if below relevant MICs, AGPs can still impede bacterial growth (rate) and production of various virulence factors, with the potential to impact, any or all of, GIT microbial populations, concentrations of harmful metabolites, initiation and clearance of (subclinical) infections, intestinal structure and dimensions, and stimulation, response, and efficacy of host defense mechanisms.
INTESTINAL MICROBIOTA AND THE HOST
The host's response to their intestinal microbial community (and associated microbial products) influences the impact of the gut microbiota on the host's health and growth performance. The relationship between the GIT microbial community and the intestinal tissue is both intricate and dynamic. The intestine plays an essential role in enabling the digestion and absorption of nutrients and preventing the passage of undesirable foreign material (e.g., microbes, detrimental microbial products, etc.) from the external environment. The clearest demonstration of the relationship between the GIT microbiota and the intestine is that germ-free animals have underdeveloped mucosal immunological tissues compared to conventional animals (Berg and Savage, 1975) . Conversely, it has been shown that raising chicks in poor sanitary conditions depresses weight gain and feed efficiency and results in increased plasma interleukin-1 (IL-1) concentrations, which play a key role in inflammatory immune responses (Roura et al., 1992) . The pro-inflammatory and negative performance effects of the poor sanitary environment were counteracted by the addition of antibiotics to the chicks' diet in the study. Therefore, the gut microbiota is necessary for the proper immunological development of the intestine and host but a sub-optimal microbiota can induce pro-inflammatory host immune responses that are detrimental to efficient growth performance. The improved performance and reduction of inflammatory markers with antibiotics have contributed to suggestions of direct immunomodulatory (antiinflammatory) effects to explain the mode of action of AGPs (Niewold, 2007 ). An optimal immune response needs a good balance between pro-inflammatory (to eliminate the pathogen) and anti-inflammatory (to manage the inflammatory response) mechanisms (Selvaraj, 2012) . The inflammatory response is essential for the interception and neutralization of foreign material that penetrates body surfaces exposed to the external environment. The innate, non-specific arm of the immune system, which includes mucosal surfaces, is the first line of defense against invading pathogens and has the greatest metabolic cost for the animal. Once mucosal barriers have been breached, foreign material/conserved pathogen-associated molecular patterns (PAMPs) will first encounter and be detected by intraepithelial leukocytes, including professional phagocytes (e.g., macrophages, dendritic cells, heterophils (neutrophils)). The phagocytes engulf, kill, and process extracellular pathogens (primarily through enzyme-based processes) and present antigen to T and B lymphocytes, which comprise the acquired arm of the immune system that is responsible for subsequent, specific immune responses (e.g., antibodies). Activated phagocytes secrete cytokines and chemokines, some notably pro-inflammatory (e.g., IL-1, IL-6), that direct other immune cells to the site of infection and help initiate an acute phase protein (APP) response by the liver (e.g., serum amyloid A, α1-acid glycoprotein, etc.), with the APPs involved in many crucial metabolic and immune pathways (O'Reilly and Eckersall, 2014) . In vivo work has shown that, when comparing a traditional AGP (salinomycin) to some potential alternatives to AGPs under challenge conditions, the relationship between suppression of inflammatory gene expression and broiler chicken performance was not particularly clear (Lu et al., 2014) , potentially underlining the desire for balance between pro-and anti-inflammatory immune mechanisms and that simple suppression of inflammatory-related responses does not necessarily promote better bird performance.
There is good evidence that antibiotics can modulate phagocyte functions but most studies have been conducted in vitro, show variable responses (increase, decrease or no effect) between antibiotics or conflicting results for the same antibiotic depending on cell type and technique used, and invariably use therapeutic antibiotic concentrations (Labro, 2000) . Macrolides may be used to treat or help manage respiratory diseases and part of the efficacy is considered to be due to anti-inflammatory effects (Babu et al., 2013) . However, macrolides may represent a particularly well studied and special antimicrobial class in this regard due to their seemingly superior ability to concentrate in phagocytes, even compared to other antimicrobial classes that have been used as AGPs (Niewold, 2007) , and, although it is difficult to be precise about exact AGP usage, macrolides are only one of numerous antimicrobial classes that have been used effectively as AGPs (Table 1) . It is also worth noting that gastrointestinal complaints are the most common adverse effects in patients receiving macrolide therapy (Zarogoulidis et al., 2012) . Moreover, while host immunity helps shape the composition of the GIT microbiota (Kogut, 2013) , to achieve this with sub-therapeutic AGP concentrations reaching/accumulating in appropriate (immune) cells to influence immune status and thus moderate the pro-inflammatory response, and in turn modulate the GIT microbiota, seems a protracted and less probable chain of events for the primary mechanism. Given the evidence presented in this paper, it seems more likely that the main effects of AGPs are via beneficial (sub-inhibitory) influences on the dynamics of the GIT microbiota and that reductions in pro-inflammatory mediators reflect a resultant change in gut-associated lymphoid tissue (GALT) interactions/stimulation.
CONCLUSION
This paper proposes that sub-inhibitory effects of antibiotics (i.e., effects when antibiotic concentrations are below MIC) are responsible for the main effects of AGPs. When below MICs, antibiotics can still influence the growth profile, production of virulence factors, and susceptibility to host defenses of affected bacteria, the effects of which would be detected as those in vivo parameters that are observed to change with AGP use and/or are suggested as the mode of action(s) (e.g., changes to GIT bacterial populations). Direct effects of AGPs on immune cells are possible, but it is suggested that indirect effects, by influencing microbial (or their products) interactions with the GALT, are more likely. An optimum immune system displays balance between pro-inflammatory and anti-inflammatory mechanisms and care is needed when attempting to alter this balance. Indeed, suppression of the pro-inflammatory response may not be beneficial, as it may make the initial immune response less effective and exacerbate microbial challenge, which is not typically associated with AGP use in practice. Regardless of diet, animal species, breed or strain, underlying immune function, etc., AGPs are considered to give relatively consistent animal performance responses across production systems. One consistent feature of all relevant animal species, regardless of specific rearing conditions, is that their GIT will harbor a mix of bacteria that can be divided as either gram-positive or gram-negative, both of which can thus be influenced by any sub-inhibitory effects of an AGP according to its spectrum of activity (Table 1) . If seeking appropriate alternatives to AGPs, it seems logical to consider any fairly consistent features of AGPs. In this regard, most AGPs have activity against at least gram-positive bacteria. Therefore, AGP alternatives that target gram-positive bacteria (with minimal resistance risk), with established and advantageous subinhibitory effects, and some appropriate immunomodulatory properties, may provide the best candidates to pursue further.
